Tags : Idera Pharmaceuticals

AbbVie Signs a Research Agreement with Idera Pharmaceuticals to Evaluate

Shots: AbbVie and Idera collaborated to conduct clinical study evaluating the combination of ABBV-368 + tilsotolimod + CT or ABBV-181. AbbVie will be responsible for conducting the trial while Idera to provide clinical trial supply of tilsotolimod The P-Ib study will evaluate the safety, tolerability, PK and preliminary efficacy of ABBV-368 plus tilsotolimod in three […]Read More